Than Aye, MD
Hematology & Oncology · Lawton, OKNPI 1104053792
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Incyte Corporation at 57.5% of the total. Reporting peaked in 2023 at $4,236 and has fallen 93.1% since, to $293 in 2025.
Across 96 payments — averaging $76.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$4K
- AstraZeneca$1K
- Genentech USA, Inc.$252
- Novocure GmbH$200
- GSK$125
- Daiichi Sankyo Inc.$125
- plus $1K from 27 others
Across 1 payment — averaging $453,526 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$454K
What the payments were for
- Consulting fees$4,04355%
- Speaking & faculty fees$2003%
- Travel & lodging$1,31918%
- Food & beverage$1,79224%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 9 | $4,246 |
| AstraZeneca(2 entities) | 7 | $1,361 |
| Genentech USA, Inc. | 10 | $252 |
| Novocure GmbH | 1 | $200 |
| GSK | 1 | $125 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Pfizer | 7 | $119 |
| Johnson & Johnson | 6 | $97 |
| Merck | 6 | $90 |
| Sanofi | 4 | $83 |
| Puma Biotechnology, Inc. | 4 | $80 |
| Novartis | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 5 | $61 |
| Boehringer Ingelheim | 3 | $59 |
| Bristol Myers Squibb | 3 | $46 |
| Foundation Medicine, Inc. | 3 | $34 |
| Lilly USA, LLC | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Seagen Inc. | 2 | $28 |
| Gilead | 2 | $27 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Amgen | 1 | $20 |
| Exelixis Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| EMD Serono, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Verastem, Inc. | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Tesaro, Inc. | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,388 in reported general payments places this provider in the 75th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 55 | $655,542 |
| VerzenioAbemaciclib | 43 | $650,173 |
| NubeqaDarolutamide | 52 | $565,963 |
| PomalystPomalidomide | 25 | $500,827 |
| RevlimidLenalidomide | 30 | $413,045 |
| JakafiRuxolitinib Phosphate | 29 | $329,465 |
| KisqaliRibociclib Succinate | 24 | $311,192 |
| OnuregAzacitidine | 13 | $283,232 |
| ImbruvicaIbrutinib | 17 | $250,882 |
| XtandiEnzalutamide | 23 | $231,284 |
| IbrancePalbociclib | 15 | $224,919 |
| TukysaTucatinib | 11 | $221,012 |
| TagrissoOsimertinib Mesylate | 13 | $216,294 |
| BrukinsaZanubrutinib | 26 | $192,575 |
| SprycelDasatinib | 23 | $160,601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Onureg, Sprycel | $61 | $944,66061 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $31 | $650,34876 claims |
| BayerNubeqa | $15 | $565,96352 claims |
| Bristol Myers SquibbRevlimid | $46 | $413,04530 claims |
| AstraZenecaTagrisso, Calquence | $1,361 | $357,82128 claims |
| Incyte CorporationJakafi | $4,246 | $329,46529 claims |
| NovartisKisqali | $66 | $311,19224 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $20 | $250,88217 claims |
| PfizerIbrance, Eliquis | $119 | $244,59145 claims |
| Seagen Inc.Tukysa | $28 | $221,01211 claims |
| Johnson & JohnsonXarelto | $97 | $27,76029 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $30 | $51348 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Lawton
- Manal Robin-HannaLawton$14K
- Vinicius Machado JorgeLawton$10K
- Anmol BaranwalLawton$4K
- Romeo MandanasOklahoma City$160K
- Caleb ScheckelTulsa$159K
- Hassan KaleemTulsa$137K
- Sanjaykumar HapaniEdmond$125K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.